The problem is that not enough revenue is coming in from sales to underpin any production capability.
That will be the Achilles heel for MXC.
Ann: Results of CimetrA bioanalytics pre-clinal trial, page-20
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RGT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.48M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1349 | 32.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.0¢ | 100 | 1 |
View Market Depth
| Last trade - 09.00am 13/09/2024 (20 minute delay) ? |
| RGT (ASX) Chart |
Day chart unavailable